FDA Approved Indications for this Orphan Drug:

Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years to 4 years of age.

FDA Marketing Approval issued as of:
09/30/2014

Orphan Drug exclusivity ends on:
09/30/2021
Company Making and Marketing this drug:
AbbVie Inc.

FDA Designation Date:
3/21/05

FDA Drug Designation:
Treatment of juvenile rheumatoid arthritis